Microbot Medical® to Participate at the 38th Annual Roth Conference

Core Insights - Microbot Medical Inc. is preparing for the full market release of its LIBERTY Endovascular Robotic System in April 2026, following a successful limited market release that began in late 2025 [3][4] - The company will present at the Roth Annual Growth Conference on March 23, 2026, where CEO Harel Gadot will discuss recent achievements and the unique aspects of the LIBERTY system [1][2] Company Overview - Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY system is the first FDA cleared, single-use, remotely operated robotic solution designed for precision, efficiency, and safety in peripheral endovascular procedures [3][4] Market Strategy - The company aims to leverage the Roth conference to showcase its commercial momentum and growth story to a diverse audience, which is expected to support its current position and future growth [3] - The LIBERTY system addresses critical unmet healthcare needs, including physician safety and staffing issues, which are increasingly important in the medical field [3]